News >

Frontline Icotinib Improves PFS Versus Chemo in EGFR+ NSCLC

Jason Harris
Published: Wednesday, Sep 06, 2017

lung cancer
Icotinib (Conmana) was associated with a 3.3-month increase in median progression-free survival (PFS) compared with chemotherapy in patients with stage IIIB/IV non–small cell lung cancer (NSCLC) in the phase III Chinese CONVINCE trial.

<.001). Those patients were also more than 8 times more likely to require drug discontinuation due to AEs (17.5% vs 2%).
Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study [published online August 23, 2017]. Ann Oncol. doi: 10.1093/annonc/mdx359.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Community Practice Connections™: 3rd Annual School of Gastrointestinal Oncology® (SOGO®)Jun 29, 20191.5
Publication Bottom Border
Border Publication
x